Omada for Cholesterol closes a critical gap in cardiovascular care, delivering between-visit support for the many adults whose LDL remains uncontrolled under usual care¹SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit healthcare provider, today announced the expansion of its integrated platform to include dedicated cholesterol management alongside weight, glucose, blood pressure, and GLP-1 support. Up to 70% of adults with obesity have high chole ...

Core Viewpoint - Omada Health will release its fourth quarter and full year 2025 results on March 5, 2026, after market close, followed by a conference call to discuss the results [1]. Company Overview - Omada Health (Nasdaq: OMDA) aims to address deficiencies in chronic care management, particularly for conditions requiring ongoing support between doctor visits, such as obesity, diabetes, hypertension, and musculoskeletal disorders [2]. - The company employs a virtual-first model that integrates human-led care teams, connected devices, and AI-enabled technology to provide personalized care at scale, including support for GLP-1 therapy [2]. - Since its inception, Omada has served over one million members across more than 2,000 employers, health plans, and health systems [2].

Core Insights - Omada Health is presenting for the first time as a public company, highlighting its transition from a private entity to a public one [1] - The company's mission focuses on addressing chronic diseases affecting 156 million Americans, aiming to improve the quality of care provided to these patients [3] Company Overview - Omada Health operates as a "between visit provider," indicating its role in offering healthcare services that supplement traditional medical visits [2] - The company was co-founded by Sean Duffy, who serves as the CEO and Director, emphasizing the leadership's commitment to the healthcare sector [2] Industry Context - The healthcare industry faces significant challenges with chronic diseases, necessitating innovative solutions to improve patient outcomes [3] - The prevalence of chronic diseases in the U.S. presents a substantial market opportunity for companies like Omada Health to deliver targeted care [3]

Omada Health FY Conference Summary Company Overview - **Company**: Omada Health (NasdaqGS:OMDA) - **Industry**: Digital Health and Chronic Disease Management - **Mission**: To bend the curve of disease and improve care for chronic disease patients, particularly those with obesity, diabetes, and other related conditions [3][4] Key Highlights Financial Performance - **Revenue**: $257 million for FY 2025, representing a **52% year-over-year growth** [6][26] - **Members Supported**: 886,000 active members [7][26] - **Adjusted Gross Margin**: Upper 60s% for LTM Q3 2025, improved from the 50s% in 2022 [26] - **Adjusted EBITDA Margin**: -2.4% for LTM Q3 2025, improved from nearly -70% in 2022, with the first positive adjusted EBITDA quarter of $2.4 million in Q3 2025 [27] Market Position and Strategy - **Target Market**: Over 20 million Americans covered by Omada's programs through 2,000+ customers, including self-insured employers and health plans [5][18] - **Expansion**: Initially focused on prediabetes and obesity, now expanded to diabetes, hypertension, and musculoskeletal (MSK) care [6][9] - **Growth Drivers**: - Multi-product offerings, including the new GLP-1 Care Track [21] - Customer-driven expansion based on demand for comprehensive care solutions [9][19] Product and Service Offerings - **Care Model**: Combines technology and personalized care to support patients between doctor visits [5][10] - **GLP-1 Care Track**: Launched to provide behavioral support alongside GLP-1 medications, addressing concerns about medication adherence and effectiveness [21][22] - **Engagement Metrics**: Over 55% of members remain engaged after 12 months, and 50% after two years [14][15] Clinical and Economic Outcomes - **Clinical Evidence**: 30 peer-reviewed publications demonstrating the effectiveness of Omada's programs [15][16] - **Economic Value**: Expected ROI of 3-6x in musculoskeletal care, with gross healthcare savings of $1,000-$1,500 per member [16][26] Future Outlook - **Investment Focus for 2026**: Emphasis on AI initiatives and enhancing prescribing capabilities to drive long-term growth and margin expansion [41][42] - **Market Trends**: Increased focus on chronic disease management from government and employers, with potential opportunities in Medicare Advantage [54][56] - **Customer Demand**: Growing interest in combining prescribing with behavioral management for chronic conditions [43][44] Additional Insights - **Customer Relationships**: Strong demand for multi-product solutions, with 75% of new clients opting for more than one condition [52] - **Regulatory Environment**: Positive dialogue with government regarding chronic disease management, indicating potential for future partnerships [54][56] - **Technological Integration**: Use of AI to enhance member experience and operational efficiency, with features like nutritional intelligence agents [38][39] This summary encapsulates the key points from Omada Health's FY conference, highlighting the company's growth, strategic direction, and the evolving landscape of chronic disease management.

Core Insights - Omada Health announced preliminary, unaudited revenue for Q4 and fiscal year 2025, indicating strong growth ahead of the J.P. Morgan Healthcare Conference [1][4] Financial Performance - Q4 2025 revenue is projected to be between $72 million and $74 million, reflecting a year-over-year increase of 50% to 54% compared to Q4 2024 [2] - For the full year 2025, revenue is expected to be between $256 million and $258 million, representing growth of 51% to 52% compared to 2024 [2] Membership Growth - Total members reached approximately 886,000 as of December 31, 2025, marking a 55% increase year-over-year [2] Business Model and Strategy - The company emphasizes the relevance of its between-visit care model, which integrates human-led care teams, connected devices, and AI technology to provide personalized care [4][5] - Enhancements in GLP-1 care offerings and AI utilization are aimed at improving member outcomes and adapting to changing healthcare dynamics [4]

Financial Results - Omada Health, Inc. announced preliminary unaudited revenue for Q4 and fiscal year 2025, with results subject to final audit adjustments[5]. - The press release detailing the financial results is attached as Exhibit 99.1 to the Current Report on Form 8-K[5]. Events - The company is participating in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California[5].

Core Insights - Omada Health's program, when paired with GLP-1 medications, demonstrates significant weight loss and persistence compared to real-world evidence, highlighting its value for employers in managing weight loss medication complexities [1][2][3] Program Outcomes - Members who remained in the program for 12 months experienced an average weight loss of 18.4%, significantly higher than the 11.9% weight loss reported in real-world evidence [2] - Omada members achieved 47% greater average weight loss on semaglutide and 37% greater weight loss on tirzepatide compared to published real-world evidence [2] - Overall, members in the program, regardless of medication persistence, achieved an average weight loss of 16.3%, nearly double that observed in real-world analyses [2] Medication Persistence - 67% of Omada members maintained their GLP-1 medication for one year, surpassing the 47-49% persistence rate found in comparable studies [4] - Members who discontinued medication before one year had an average weight loss of 13.1%, compared to 6.8% among similar patients in other studies [4] Support and Care Model - Omada's Enhanced GLP-1 Care Track provides comprehensive support, helping members navigate their weight loss journey and manage medication side effects [5] - The program combines specialized care team support with tailored content to optimize the medication experience for members [5] Real-World Data and Research - Omada emphasizes the importance of real-world data, tracking outcomes in real-time to ensure the effectiveness of its program as medications and access evolve [6] - The study is part of the Omada Insights Lab ANSWERS Initiative, which focuses on analyzing real-world evidence related to weight medication [6] Company Overview - Omada Health is a virtual healthcare provider addressing cardiometabolic conditions and supporting members taking GLP-1 and other anti-obesity medications [8] - The company has served over one million members and has published 30 peer-reviewed studies demonstrating its clinical and economic results [9]

Core Insights - Omada Health's 12-month analysis of its GLP-1 companion program shows significant weight loss among participants, with an average of 18.4% weight loss for those who persisted on medication, compared to 11.9% in real-world evidence [1][2] - The program demonstrated that members achieved 47% greater weight loss on semaglutide and 37% greater weight loss on tirzepatide compared to published real-world evidence [1][2] - Overall, participants in the program experienced an average weight loss of 16.3%, nearly double that observed in real-world analyses [1][2] Program Effectiveness - 67% of Omada members remained on their GLP-1 medications for one year, surpassing the 47-49% persistence rate found in comparable studies [2] - Members who discontinued medication before one year achieved a 13.1% average weight loss, compared to 6.8% among similar patients in other studies [2] Support and Care Model - Omada's Enhanced GLP-1 Care Track provides comprehensive support, helping members navigate their weight loss journey and manage medication side effects [3] - The program combines specialized GLP-1-focused care team support with tailored content, enhancing the medication experience for members [3] Real-World Data and Insights - Omada emphasizes the importance of real-world data, tracking outcomes in real-time to ensure the effectiveness of its programs as medications and access evolve [4] - The study is part of the Omada Insights Lab ANSWERS Initiative, which analyzes real-world data from behavior change weight health programs [4] Company Overview - Omada Health is a virtual healthcare provider focused on cardiometabolic conditions, including obesity, and supports members taking GLP-1s and other anti-obesity medications [5] - The company has served over one million members and has over 30 peer-reviewed publications demonstrating its clinical and economic results [6]

Core Insights - Omada Health will participate in the 44th Annual J.P. Morgan Healthcare Conference, presenting on January 14, 2025 [1] Company Overview - Omada Health is a virtual healthcare provider focusing on cardiometabolic conditions such as diabetes, hypertension, prediabetes, and obesity, as well as musculoskeletal issues [2] - The company employs a unique approach called Compassionate Intelligence, which integrates human-led care teams, connected devices, and AI technology to provide personalized care at scale [2] Performance and Reach - With over a decade of experience, Omada has published 30 peer-reviewed studies demonstrating its clinical and economic outcomes [3] - The company has served over one million members and has partnered with more than 2,000 customers, including pharmacy benefit managers, health plans, health systems, and employers from small businesses to Fortune 500 companies [3] - Omada's evidence-based approach has led to multiple healthcare accreditations and industry recognition [3] Impact on Healthcare - As a trusted partner in the healthcare ecosystem, Omada aims to improve health outcomes and manage healthcare costs effectively [4]

Core Insights - Omada Health will participate in the 44th Annual J.P. Morgan Healthcare Conference, presenting on January 14, 2025 [1] Company Overview - Omada Health is a virtual healthcare provider focusing on cardiometabolic conditions such as diabetes, hypertension, prediabetes, and obesity, as well as musculoskeletal issues [2] - The company employs a unique approach called Compassionate Intelligence, which integrates human-led care teams, connected devices, and AI technology to provide personalized care at scale [2] Performance and Reach - With over a decade of experience, Omada has published 30 peer-reviewed studies demonstrating its clinical and economic outcomes [3] - The company has served over one million members and has partnered with more than 2,000 customers, including pharmacy benefit managers, health plans, health systems, and employers from small businesses to Fortune 500 companies [3] - Omada's evidence-based approach has led to multiple healthcare accreditations and industry recognition [3] Impact on Healthcare - As a trusted partner in the healthcare ecosystem, Omada aims to improve health outcomes and manage healthcare costs effectively [4]